NIH/NCATS is accepting pre-proposal applications to collaborate with our pre-clinical scientists to develop human cell-based platforms and advance promising compounds for pain, addiction and overdose.
The research collaborations aim to:
Identify and de-risk potential therapies that work in new ways through the development of assays (tests), high-throughput screening and the optimization of promising compounds.
Accelerate the identification of promising chemical structures and develop them into pharmacological or drug-like compounds.
Advance promising new drug candidates through rigorous pre-clinical efficacy and safety studies for first-in-human clinical trials as required by the U.S. Food and Drug Administration.
Pre-proposal submissions are accepted and reviewed on a rolling basis. Submissions for Cycle II are due by July 18, 2019. The call for proposals webpage has additional details, including a PDF with detailed application instructions. For more information, email us at NCATSDPIHEALCollab@nih.gov.